Monday, February 8, 2016 5:14:00 AM PDT | VentureDeal
Cambridge, Massachusetts -- Biotechnology research company Affinivax has received $2.5 million in additional development investment.
Affinivax is developing a "novel conjugation technology with the goal of designing vaccines that provide broad protection against challenging diseases afflicting children and adults in both the developing and developed worlds." The additional financing was provided by the Bill and Melinda Gates Foundation. Affinivax Said it intends to use the funding to advance its MAPS vaccine which targets Streptococcus pneumoniae. Pres. and CEO Steven Brugger has been with the firm since 2013.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
